China Resources Pharmaceutical filed with the Hong Kong exchange to raise $368.5 million in an investment fund.
China Resources Pharmaceutical filed with the Hong Kong exchange to raise $368.5 million in an investment fund. The fund will be run by its subsidiary, CR Pharm (Shantou). It will make equity investments in China pharma companies, though it was not disclosed whether the fund’s character will be venture or private equity. CR Pharm, China’s second-largest drugmaker, staged a $1.8 billion IPO in Hong Kong last year. Three of its subsidiaries are listed companies in China.
